

# **Key Investor Information**

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

# ARK GENOMIC REVOLUTION UCITS ETF

Share Class: USD ACCUMULATING ETF

### ISIN: IE00005M6X01

The Fund is a sub-fund of ARK Invest UCITS ICAV (the "ICAV")

The Fund is managed by IQ EQ Fund Management (Ireland) Limited (the "Manager") of the IQ EQ group of companies

#### **Objectives and Investment Policy**


The ARK Genomic Revolution UCITS ETF (the "Fund") is actively managed and invests primarily in global equity securities of companies involved in the genomic revolution. These are companies that are substantially focused on or benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bioinspired computing, bioinformatics, molecular medicine and agricultural biotechnology.

The investment manager uses both "top down" approaches (thematic research sizing the potential total available market for each technology, and identifying the prime leaders, enablers and beneficiaries of the innovation) and "bottom up" approaches (valuation, fundamentals and quantitative measures relating to individual companies) to select companies. The "top down" approach explicitly selects for technologies that the Investment Manager anticipates will make a meaningful contribution to at least two of the United Nations Sustainable Development Goals. The "bottom up" approach to company selection integrates ESG considerations such as business involvement, violations of international norms and standards and an assessment of controversies, environmental and social risks and governance.

**DIVIDEND POLICY**. This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be re-invested into the Fund.

**DEALING**. Shares in this Share Class (the "**Shares**") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the ICAV. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on https://arkeurope.com/

#### **Risk and Reward Profile**



- Historical data may not be a reliable indication for the future.
- The risk category shown is not guaranteed and may shift over time.
- The lowest category does not mean 'risk free'.

The Fund is rated 7 due to the nature of its investments and its risks. The rating is calculated based on historical data and may not be a reliable indication of the Fund's future risk profile. The risk category may shift over time. The lowest category on the above scale does not mean "risk free".

The Fund is subject to the risks associated with technology-focused companies (including biotechnology and pharmaceutical companies) including the risk of: (1) failure of new technologies and solutions to replace existing ones or to be approved by governments/regulators or to achieve their aim; (2) the failure of individual companies to successfully capitalise on such new technologies and reach profitability; (3) competition, including rapid developments in competitive technologies (which may leave a company's products out-of-date); (4) government intervention or excessive regulation, delays to approvals or lack of financial support; and (5) legal attacks from competitors.

**Other:** (1) The Fund also invests in small publicly-traded companies which may be less mature and more vulnerable to adverse business or economic events and greater share price changes than larger companies, the wider technology sector or stock market. (2) The Fund invests in global equity securities and there is a risk of loss arising from exchange rate fluctuations or exchange control regulations. (3) The ICAV's depositary or other service providers may go bankrupt and fail to return money or property belonging to the Fund. (4) It may not always be possible to buy and sell the Fund's shares on a stock exchange or at prices closely reflecting the Fund's Net Asset Value. (5) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund.

#### Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

| One-off charges taken before or after you invest |  |
|--|--|
| Entry charge                                     | No charge                                      |
| Exit charge                                      | No charge                                      |
| Charges taken from the Fund over a year          |  |
| Ongoing charges                                  | 0.75%  |
|  |  |
| Charges taken from the Fund u                    | under certain specific conditions              |
| Charges taken from the Fund u<br>Performance fee | under certain specific conditions<br>No charge |
|  | ·  |
|  | ·  |

\*Authorised Participants dealing directly with the ICAV will pay dealingrelated transaction costs.

Investors who buy and sell Shares on stock exchanges are not charged entry or exit charges by the ICAV but may be charged dealing costs and fees by their stockbroker. Please consult your stockbroker and/or investment adviser for details of such fees.

The ongoing charges figure is an estimate of the charges that will be deducted from the Share Class over the course of a year. The ongoing charges figure excludes portfolio transaction costs (except for transaction costs paid to the Depositary, which are included).

For more information about charges, please see the "Fees, Costs and Expenses" and "Subscriptions and Redemptions" sections of the ICAV's Prospectus and the "Fees and Expenses" and "Dealing in Shares of the Fund" sections of the Fund Supplement which are available at: https://arkeurope.com/

## Past Performance

- The Fund has been in existence since March 2024. This Share Class has been in existence since March 2024.
- There is insufficient data to provide a useful indicator of past performance to investors.

# Practical Information

- Fund Depositary: Northern Trust Fiduciary Services (Ireland) Limited.
- The ICAV is resident in Ireland for taxation purposes. This may have an impact on your personal tax position. Please consult your investment or tax adviser for advice on your own tax liabilities.
- The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Prospectus.
- Switching of shares between this Share Class and other share classes of the Fund and/or other sub-funds of the ICAV is not permitted.
- The Fund is one of a number of sub-funds of the ICAV. The assets and liabilities of each sub-fund are segregated from each other by Irish law. Although the rights of investors and creditors are normally limited to the assets of each sub-fund, the ICAV is a single legal entity that may operate in jurisdictions which may not recognise such segregation.
- Further information about the Fund and the Share Class can be obtained from the ICAV's Prospectus and Fund Supplement and the annual and interim financial statements (that are prepared for the ICAV as a whole), which are available in English and certain other languages, in addition to the latest available Net Asset Value for the Share Class and details of the Fund's portfolio, at: https://arkeurope.com/
- Details of the Manager's up-to-date policy in respect of remuneration, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding same can be accessed from the following website: www.igeq.com/policy- documents
- An indicative intra-day net asset value ("iNAV") for the Share Class will be available at: https://arkeurope.com/

The ICAV is authorised in Ireland and regulated by the Central Bank of Ireland. The Manager is authorised in Ireland and regulated by the Central Bank of Ireland.

This Key Investor Information is accurate as at 19 February 2025.